Login
$RCKT
$2.19 +$0.03 (1.39%) After hours

$RCKT 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027

06 Oct 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2026, and is entered into by and among ROCKET PHARMACEUTICALS, INC., a Delaware corporation (“Company”), its Subsidiaries SPACECRAFT SEVEN, LLC, a Delaware limited li...

15 Sep 2026 8-K: Regulation FD Disclosure

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol

27 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

10 Aug 2026 8-K: Results of Operations and Financial Condition

All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other significant safety con...

03 Aug 2026 8-K: Regulation FD Disclosure

Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed

30 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

12 Jun 2026 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

CRANBURY, NJ – June 12, 2026 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today a...

21 May 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 Annual Meeting of Stockholders of Rocket Pharmaceuticals, Inc. (the “Company”) was held on May 20, 2026 (the “Annual Meeting”). At the Annual Meeting, there were present, in person or by proxy, holders of 80,774,659 shares of co...

07 May 2026 8-K: Results of Operations and Financial Condition

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated

28 Apr 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline

27 Mar 2026 8-K: Regulation FD Disclosure

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2

10 Mar 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Rocket Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

26 Feb 2026 8-K: Results of Operations and Financial Condition

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

06 Nov 2025 8-K: Results of Operations and Financial Condition

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026

14 Oct 2025 8-K: Other Events

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

03 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

03 Oct 2025 8-K: Other Events

On October 3, 2025, Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) reported that it has voluntarily withdrawn its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for mozafancogene autotemc...

29 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

17 Sep 2025 8-K: Entry into a Material Definitive Agreement

This letter (the “Agreement and Release”) confirms our agreement with regard to the resignation of your employment with Rocket Pharmaceuticals, Inc. (“the Company”) effective December 31, 2025 (the “Separation Date”). For avoidance of do...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support